Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Amyloid PET in Sporadic Early- Versus Late-Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts.

Amyloid PET in Sporadic Early- Versus Late-Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts. Annals of neurology Lagarde, J., Maiti, P., Schonhaut, D. R., Blazhenets, G., Zhang, J., Eloyan, A., Thangarajah, M., Taurone, A., Allen, I. E., Soleimani-Meigooni, D. N., Zeltzer, E., Windon, C., Abu Raya, M., Vrillon, A., Smith, K., Shankar, R., Amuiri, A., Rocha, S., Hammers, D. B., Dage, J. L., Nudelman, K. N., Kirby, K., Aisen, P., Koeppe, R., Landau, S. M., Carrillo, M. C., Touroutoglou, A., Brickhouse, M., Vemuri, P., Beckett, L., Raman, R., Atri, A., Day, G. S., Duara, R., Graff-Radford, N. R., Honig, L. S., Jones, D. T., Masdeu, J. C., Mendez, M. F., Womack, K., Musiek, E., Onyike, C. U., Riddle, M., Grant, I. M., Rogalski, E., Johnson, E. C., Salloway, S., Sha, S., Turner, R. S., Wingo, T. S., Wolk, D. A., Dickerson, B. C., Apostolova, L. G., La Joie, R., Rabinovici, G. D. 2025

Abstract

Early-onset Alzheimer's disease (EOAD) and late-onset Alzheimer's disease (LOAD) differ in many respects. Here, we address the issue of possible differences in fibrillar amyloid pathology as measured by positron emission tomography (PET), which remains unresolved due to the lack of large-scale comparative studies.Three hundred ninety-nine cognitively impaired participants younger than 65?years of age from the multicenter Longitudinal Early-onset Alzheimer's Disease Study (LEADS) and 450 cognitively impaired participants older than 65?years from the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent clinical assessment, brain magnetic resonance imaging (MRI), and amyloid PET and were included in this study. We compared amyloid PET outcomes (positivity rate based on visual read and quantified tracer uptake expressed as Centiloids [CLs]) between the 2 cohorts and studied their association with age, sex, APOE genotype, and cognition.The amyloid positivity rate was higher in LEADS (78%, 95% confidence interval [CI]?=?74-82) than in ADNI (71%, 95% CI?=?67-75, p?=?0.02). Lower Mini-Mental State Examination (MMSE) and APOE4 genotype increased the odds of amyloid positivity in both cohorts. Visually positive scans had higher CLs in LEADS (EOAD, mean?=?95.3?±?26.1) than in ADNI (LOAD, mean?=?80.9?±?36.8, p?

View details for DOI 10.1002/ana.27233

View details for PubMedID 40091774